Published in J Clin Oncol on August 11, 2014
Enhancing the efficacy of radiation therapy: premises, promises, and practicality. J Clin Oncol (2014) 0.81
Emerging Treatment Paradigms in Radiation Oncology. Clin Cancer Res (2015) 0.79
Radiation oncology: a snapshot in time, 2014. J Clin Oncol (2014) 0.79
MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Oncotarget (2016) 0.79
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes. J Clin Oncol (2014) 0.76
Microfluidics as a new tool in radiation biology. Cancer Lett (2015) 0.75
Role of SGK1 for fatty acid uptake, cell survival and radioresistance of NCI-H460 lung cancer cells exposed to acute or chronic cycling severe hypoxia. Radiat Oncol (2016) 0.75
Reducing radiation-induced gastrointestinal toxicity - the role of the PHD/HIF axis. J Clin Invest (2016) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem (1996) 8.08
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 7.52
Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (2001) 7.13
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science (1999) 6.97
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Tyrosine kinases as targets for cancer therapy. N Engl J Med (2005) 6.24
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science (2008) 4.89
Translation of the Philadelphia chromosome into therapy for CML. Blood (2008) 4.74
Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol (2004) 3.63
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 3.59
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med (2011) 2.97
Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology (2003) 2.40
The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29
Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys (1996) 2.15
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science (2009) 2.11
Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol (2004) 2.09
The monocarboxylate transporter family--role and regulation. IUBMB Life (2011) 2.07
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Innovations in image-guided radiotherapy. Nat Rev Cancer (2007) 1.98
Radiation oncology: a century of achievements. Nat Rev Cancer (2004) 1.98
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res (2008) 1.70
DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol Cancer Res (2008) 1.69
Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol (1995) 1.66
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep (2012) 1.66
A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Cancer Res (2010) 1.65
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol (2005) 1.59
PHD inhibition mitigates and protects against radiation-induced gastrointestinal toxicity via HIF2. Sci Transl Med (2014) 1.59
The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science (1988) 1.55
Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol (2010) 1.54
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A (1994) 1.52
2-deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med (2007) 1.40
Abscopal effect in a patient with melanoma. N Engl J Med (2012) 1.39
Amelioration of radiation-induced liver damage in partially hepatectomized rats by hepatocyte transplantation. Cancer Res (1999) 1.39
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer (2013) 1.39
2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res (2003) 1.34
Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol (2012) 1.29
Current status of hepatocyte transplantation. Transplantation (2012) 1.28
A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol (2008) 1.24
Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res (2013) 1.24
Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys (2001) 1.19
Radiation as an immune modulator. Semin Radiat Oncol (2013) 1.19
Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol (2012) 1.11
Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin Ther Pat (2010) 1.11
"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res (2010) 1.11
Radical irradiation of extracranial oligometastases. J Clin Oncol (2014) 1.07
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol (2008) 1.06
Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res (1990) 1.05
Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol (2011) 1.05
Interaction of radiation therapy with molecular targeted agents. J Clin Oncol (2014) 1.05
C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys (2001) 1.05
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol (2009) 1.03
Metformin: a new oral biguanide. Clin Ther (1996) 1.02
The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys (1990) 1.01
Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs (1995) 0.98
Skin hypoxia: a promoting environmental factor in melanomagenesis. Cell Cycle (2006) 0.92
Stem cell therapies for the treatment of radiation-induced normal tissue side effects. Antioxid Redox Signal (2014) 0.90
Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin. Radiother Oncol (2013) 0.89
p53 is an important factor for the radiosensitization effect of 2-deoxy-D-glucose. Int J Oncol (2009) 0.86
Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol (2001) 0.83
Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors. J Biomol Screen (2014) 0.83
Intensity-modulated radiation therapy in the treatment of head and neck cancer. Nat Clin Pract Oncol (2005) 0.83
Studies on the mechanism of action of various vasodilators. Br J Pharmacol (1980) 0.82
Simultaneous administration of glucose and hyperoxic gas achieves greater improvement in tumor oxygenation than hyperoxic gas alone. Int J Radiat Oncol Biol Phys (2001) 0.82
Evaluation of Diabetic Patients with Breast Cancer Treated with Metformin during Adjuvant Radiotherapy. Int J Breast Cancer (2013) 0.80
Fractionated external beam radiotherapy as a suitable preparative regimen for hepatocyte transplantation after partial hepatectomy. Int J Radiat Oncol Biol Phys (2011) 0.80
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res (2002) 0.77